Defiance Daily Target 2X Short LLY ETF(LLYZ.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Defiance Daily Target 2X Short LLY ETF
LLYZ.US
News
View More

Eli Lilly (LLY) Valuation Check After Breakthrough Therapy Status For Sofetabart Mipitecan

Eli Lilly (LLY) has received FDA Breakthrough Therapy designation for its candidate sofetabart mipitecan in treating platinum-resistant ovarian cancer, shifting focus back to oncology. The stock has shown volatility with a 1-day return of 2.12% and a 30-day return of 1.25%, but a strong 90-day return of 28.78% and a 1-year return of 36.52%. Currently trading at $1,064.29, it is about 4% below the average analyst price target of $1,189.18, suggesting it may be undervalued. Analysts project significant growth in sales for its tirzepatide franchise, raising questions about future pricing and valuation risks.

Simplywall·
US
LLY
-1.51%
US
ELIS
+1.35%
US
LLYX
-2.87%
Simplywall·
US
LLY
-1.51%
US
ELIS
+1.35%
US
LLYX
-2.87%

Eli Lilly & Co. Stock Underperforms Tuesday When Compared To Competitors

Eli Lilly & Co. (LLY) shares fell 2.19% to $1,039.51 on Tuesday, marking the third consecutive day of losses. The stock is currently 8.33% below its 52-week high of $1,133.95. In contrast, competitors like Johnson & Johnson, Pfizer, and AbbVie saw gains. The trading volume was 2.6 million, below the 50-day average of 3.2 million. The overall market showed mixed results, with the S&P 500 up 0.41% and the Dow down 0.83%.

Dow Jones·
US
LLYX
-2.87%
US
ELIL
-2.84%
US
JNJ
+1.46%
Dow Jones·
US
LLYX
-2.87%
US
ELIL
-2.84%
US
JNJ
+1.46%

Some of Pharma's Biggest Brands Face a New Reality (Status: Pending)

Big pharma faces new pricing pressures as Medicare adds 15 well-known drugs to its negotiation list, including Pfizer's Xeljanz and Novartis' Cosentyx. These drugs, used by 1.8 million Medicare beneficiaries, account for $27 billion in spending. While negotiated prices won't take effect until 2028, the move signals long-term pricing pressure on established drugs, impacting revenue for major companies like Pfizer, Novartis, and Eli Lilly.

GuruFocus·
US
ELIL
-2.84%
US
LLYZ
0.00%
US
LLYX
-2.87%
GuruFocus·
US
ELIL
-2.84%
US
LLYZ
0.00%
US
LLYX
-2.87%

A Look Into Eli Lilly and Co Inc's Price Over Earnings

Eli Lilly and Co Inc. (NYSE:LLY) shares are currently trading at $1060.01, down 0.40%. The stock has decreased by 1.76% over the past month but increased by 31.78% over the past year. Investors are advised to consider the company's price-to-earnings (P/E) ratio, which is lower than the industry average of 127.31. A lower P/E may indicate undervaluation, but it could also suggest weak growth prospects. Investors should use the P/E ratio alongside other financial metrics and qualitative factors for informed decision-making.

benzinga_article·
US
LLYZ
0.00%
US
LLYX
-2.87%
US
LLY
-1.51%
benzinga_article·
US
LLYZ
0.00%
US
LLYX
-2.87%
US
LLY
-1.51%

Resona Asset Management Co. Ltd. Sells 15,289 Shares of Eli Lilly and Company $LLY

Resona Asset Management Co. Ltd. has reduced its stake in Eli Lilly and Company (NYSE: LLY) by 5.5%, selling 15,289 shares in the third quarter. The firm now holds 263,865 shares, valued at approximately $199.7 million, making it the 14th largest position in its portfolio. Eli Lilly's stock has seen a recent decline of 2.1%, with a current price of $1,065.05. The company reported strong earnings, beating estimates with $7.02 EPS and a revenue of $17.6 billion for the quarter, reflecting a 53.9% year-over-year increase. Additionally, Eli Lilly announced a quarterly dividend increase to $1.73 per share, payable on March 10th.

Market Beat·
US
ELIL
-2.84%
US
LLYZ
0.00%
US
LLYX
-2.87%
Market Beat·
US
ELIL
-2.84%
US
LLYZ
0.00%
US
LLYX
-2.87%
© 2026 Longbridge｜Disclaimer